Maximum quantity allowed is 999
Please select the quantity
CAS RN: 13647-35-3 | Product Number: T4049
Trilostane
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 3,17β-Dihydroxy-4α,5α-4,5-epoxyandrost-2-ene-2-carbonitrile
- (4α,5α,17β)-4,5-Epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 200MG |
₹4,000.00
|
Contact Us | Contact Us |
|
| 1G |
₹14,000.00
|
2 | 7 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | T4049 |
Purity / Analysis Method 
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__0H__2__7NO__3 = 329.44 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 13647-35-3 |
| Reaxys Registry Number | 7043886 |
| MDL Number | MFCD00199295 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Specific rotation | +135 to +150 deg(C=1, pyridine) |
| NMR | confirm to structure |
Properties (reference)
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Dimethylformamide |
| Solubility (insoluble in) | Chloroform, Diethyl ether |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | BV8044200 |
Transport Information:
Application
Trilostane: A Reversible and Competitive Inhibitor of 3β-Hydroxysteroid Dehydrogenase (3β-HSD)
Trilostane is a reversible and competitive inhibitor of 3β-hydroxysteroid dehydrogenase (3β-HSD), which is the key enzyme essential for synthesis of cortisol and all other steroids. 3β-HSD has two isozymes, type1 (3β-HSD1) and type2 (3β-HSD2). 3β-HSD1 is a critical enzyme in the conversion of DHEA [D0044] to estradiol [E0919] in breast tumor cells and may be a target enzyme for inhibition in the treatment of breast cancer, whereas 3β-HSD2 participates in the production of cortisol and aldosterone in the adrenal gland.1,2) Trilostane is an inhibiter of the 3β-HSDs (type 1 and 2). Therefore, trilostane is of interest for the treatment of breast cancer in postmenopausal women2), and has been used for the treatment of Cushing's syndrome in dogs to reduce cortisol and aldosterone levels.3,4) (The product is for research purpose only.)
References
- 1) Structure/function of the inhibition of human 3β-hydroxysteroid dehydrogenase type 1 and type 2 by trilostane
- 2) Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer (a review)
- 3) Aldosterone-, Corticosterone- and Cortisol-Secreting Adrenocortical Carcinoma in a Dog: Case Report
- 4) Treating canine Cushing's syndrome: Current options and future prospects (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.